| Patient Number . | AdV Species . | AdV in Stools, Day . | AdV in Blood, Day . | AdV Maximum Copy Number in Blood, Day . | Treatment Before BCV . | AdV Copy Number at Start of BCV, Day . | BCV Doses . | Steroids at Start of BCV . | AdV Infection Resolved . | Further Viruses in the Transplant Period . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C | −83 to +26 | −25 to +26 | 4.43 × 106 +10 | CDV | 1.12 × 106 +8 | 12 | No | Yes | EBV (blood, d +34 to d +55), HSV (blood, oral, resistant to aciclovir), BK (urine, very weak in blood), HHV-6 (blood, d −15 to d −1) | Alive |
| 2 | C | +50 to +78 | +61 to +79 | 13 500 +64 | CDV | 2330, +76 | 5 | Yes | Yes | BK (urine) | Deceased +91 |
| 3 | C | +21 to +56 | +16 to +42 | 410 000 +28 | CDV | 410 000 +28 | 12 | Yes | Yes | BK (urine), EBV (resolved after rituximab) | Alive |
| 4 | Non-C | +13 to +97 | +13 to +67 | 802 000 +34 | CDV | 44 200 +51 | 4 | No | Yes | BK (urine), EBV (very weak, no specific treatment) | Alive |
| 5 | Non-C: A31 | +14 to +98 | +21 to +41 +63 to +93 | 44 100 +73 | CDV | 35 100 +27 | 6 | No | Yes | None | Alive |
| 6 | C | +14 to +38 | +21 to +84 | 1.37 × 109 +84 | CDV Ribavirin | 1.15 × 108 +51 | 6 | Yes | No | BK (urine) | Deceased +85 |
| 7 | C + non-C | +7 to +51 | +27 to +64 | 3.07 × 109 +47 | CDV, AdV-specific T cells | 2.98 × 109 +46 | 6 | No | No | EBV (blood, d +42 to d +51), HHV-6 (blood, d +34 to d +49) | Deceased +64 |
| 8 | C | +68 to +89 | +75 to +82 | 289 000 +75 | No CDV | 101 000 +77 | 10 | Yes | Yes | CMV (blood, d +19 to d +22), BK (urine) | Deceased +161 |
| Patient Number . | AdV Species . | AdV in Stools, Day . | AdV in Blood, Day . | AdV Maximum Copy Number in Blood, Day . | Treatment Before BCV . | AdV Copy Number at Start of BCV, Day . | BCV Doses . | Steroids at Start of BCV . | AdV Infection Resolved . | Further Viruses in the Transplant Period . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C | −83 to +26 | −25 to +26 | 4.43 × 106 +10 | CDV | 1.12 × 106 +8 | 12 | No | Yes | EBV (blood, d +34 to d +55), HSV (blood, oral, resistant to aciclovir), BK (urine, very weak in blood), HHV-6 (blood, d −15 to d −1) | Alive |
| 2 | C | +50 to +78 | +61 to +79 | 13 500 +64 | CDV | 2330, +76 | 5 | Yes | Yes | BK (urine) | Deceased +91 |
| 3 | C | +21 to +56 | +16 to +42 | 410 000 +28 | CDV | 410 000 +28 | 12 | Yes | Yes | BK (urine), EBV (resolved after rituximab) | Alive |
| 4 | Non-C | +13 to +97 | +13 to +67 | 802 000 +34 | CDV | 44 200 +51 | 4 | No | Yes | BK (urine), EBV (very weak, no specific treatment) | Alive |
| 5 | Non-C: A31 | +14 to +98 | +21 to +41 +63 to +93 | 44 100 +73 | CDV | 35 100 +27 | 6 | No | Yes | None | Alive |
| 6 | C | +14 to +38 | +21 to +84 | 1.37 × 109 +84 | CDV Ribavirin | 1.15 × 108 +51 | 6 | Yes | No | BK (urine) | Deceased +85 |
| 7 | C + non-C | +7 to +51 | +27 to +64 | 3.07 × 109 +47 | CDV, AdV-specific T cells | 2.98 × 109 +46 | 6 | No | No | EBV (blood, d +42 to d +51), HHV-6 (blood, d +34 to d +49) | Deceased +64 |
| 8 | C | +68 to +89 | +75 to +82 | 289 000 +75 | No CDV | 101 000 +77 | 10 | Yes | Yes | CMV (blood, d +19 to d +22), BK (urine) | Deceased +161 |
Abbreviations: BCV, brincidofovir; BK, human polyomavirus 1; CDV, cidofovir; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus-6; HSV, herpes simplex virus.
| Patient Number . | AdV Species . | AdV in Stools, Day . | AdV in Blood, Day . | AdV Maximum Copy Number in Blood, Day . | Treatment Before BCV . | AdV Copy Number at Start of BCV, Day . | BCV Doses . | Steroids at Start of BCV . | AdV Infection Resolved . | Further Viruses in the Transplant Period . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C | −83 to +26 | −25 to +26 | 4.43 × 106 +10 | CDV | 1.12 × 106 +8 | 12 | No | Yes | EBV (blood, d +34 to d +55), HSV (blood, oral, resistant to aciclovir), BK (urine, very weak in blood), HHV-6 (blood, d −15 to d −1) | Alive |
| 2 | C | +50 to +78 | +61 to +79 | 13 500 +64 | CDV | 2330, +76 | 5 | Yes | Yes | BK (urine) | Deceased +91 |
| 3 | C | +21 to +56 | +16 to +42 | 410 000 +28 | CDV | 410 000 +28 | 12 | Yes | Yes | BK (urine), EBV (resolved after rituximab) | Alive |
| 4 | Non-C | +13 to +97 | +13 to +67 | 802 000 +34 | CDV | 44 200 +51 | 4 | No | Yes | BK (urine), EBV (very weak, no specific treatment) | Alive |
| 5 | Non-C: A31 | +14 to +98 | +21 to +41 +63 to +93 | 44 100 +73 | CDV | 35 100 +27 | 6 | No | Yes | None | Alive |
| 6 | C | +14 to +38 | +21 to +84 | 1.37 × 109 +84 | CDV Ribavirin | 1.15 × 108 +51 | 6 | Yes | No | BK (urine) | Deceased +85 |
| 7 | C + non-C | +7 to +51 | +27 to +64 | 3.07 × 109 +47 | CDV, AdV-specific T cells | 2.98 × 109 +46 | 6 | No | No | EBV (blood, d +42 to d +51), HHV-6 (blood, d +34 to d +49) | Deceased +64 |
| 8 | C | +68 to +89 | +75 to +82 | 289 000 +75 | No CDV | 101 000 +77 | 10 | Yes | Yes | CMV (blood, d +19 to d +22), BK (urine) | Deceased +161 |
| Patient Number . | AdV Species . | AdV in Stools, Day . | AdV in Blood, Day . | AdV Maximum Copy Number in Blood, Day . | Treatment Before BCV . | AdV Copy Number at Start of BCV, Day . | BCV Doses . | Steroids at Start of BCV . | AdV Infection Resolved . | Further Viruses in the Transplant Period . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C | −83 to +26 | −25 to +26 | 4.43 × 106 +10 | CDV | 1.12 × 106 +8 | 12 | No | Yes | EBV (blood, d +34 to d +55), HSV (blood, oral, resistant to aciclovir), BK (urine, very weak in blood), HHV-6 (blood, d −15 to d −1) | Alive |
| 2 | C | +50 to +78 | +61 to +79 | 13 500 +64 | CDV | 2330, +76 | 5 | Yes | Yes | BK (urine) | Deceased +91 |
| 3 | C | +21 to +56 | +16 to +42 | 410 000 +28 | CDV | 410 000 +28 | 12 | Yes | Yes | BK (urine), EBV (resolved after rituximab) | Alive |
| 4 | Non-C | +13 to +97 | +13 to +67 | 802 000 +34 | CDV | 44 200 +51 | 4 | No | Yes | BK (urine), EBV (very weak, no specific treatment) | Alive |
| 5 | Non-C: A31 | +14 to +98 | +21 to +41 +63 to +93 | 44 100 +73 | CDV | 35 100 +27 | 6 | No | Yes | None | Alive |
| 6 | C | +14 to +38 | +21 to +84 | 1.37 × 109 +84 | CDV Ribavirin | 1.15 × 108 +51 | 6 | Yes | No | BK (urine) | Deceased +85 |
| 7 | C + non-C | +7 to +51 | +27 to +64 | 3.07 × 109 +47 | CDV, AdV-specific T cells | 2.98 × 109 +46 | 6 | No | No | EBV (blood, d +42 to d +51), HHV-6 (blood, d +34 to d +49) | Deceased +64 |
| 8 | C | +68 to +89 | +75 to +82 | 289 000 +75 | No CDV | 101 000 +77 | 10 | Yes | Yes | CMV (blood, d +19 to d +22), BK (urine) | Deceased +161 |
Abbreviations: BCV, brincidofovir; BK, human polyomavirus 1; CDV, cidofovir; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus-6; HSV, herpes simplex virus.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
